9 most recent filings and news items mentioning JAGX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/JAGX/news?limit=20"
Pull JAGX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayJaguar's board initiated a process to review strategic alternatives including mergers, acquisitions, and partnerships to maximize shareholder value as it completes clinical work for a rare disease intestinal failure drug. The move comes as crofelemer shows promise in reducing par
View filing at SEC.gov →Jaguar Health and Uptown Capital amended their royalty interest agreement to set a monthly minimum payment floor of $750,000 beginning October 1, 2026. The amendment modifies payment obligations under the original $12 million royalty interest issued in December 2020.
View filing at SEC.gov →Jaguar Health's board authorized the issuance of Series P non-convertible preferred stock with 300 shares designated. The filing establishes terms and conditions for this new preferred stock class, potentially indicating capital raising activity.
View filing at SEC.gov →Jaguar Health announced approval of all five proposals submitted to stockholders at its May 22, 2026 Annual Meeting of Stockholders, which was adjourned until June 8, 2026. The company also announced CEO Lisa Conte will present virtually at the Emerging Growth Conference on June
View filing at SEC.gov →Jaguar Health is converting 3.72 shares of Series Q Preferred Stock into 31,958 shares of common stock held by Streeterville Capital under a May 26, 2026 agreement. The transaction represents a dilutive equity restructuring that simplifies the capital structure.
View filing at SEC.gov →Jaguar Health received notice on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), allowing its securities to remain listed and traded on Nasdaq. The compliance reinstatement follows a 816% net revenue increase in Q1 2026 versus Q1 2025, driven by
View filing at SEC.gov →Jaguar Health agreed to exchange 4 shares of Series Q Perpetual Preferred Stock held by Streeterville Capital for 27,247 shares of common stock under Section 3(a)(9) of the Securities Act. The exchange represents a conversion of preferred equity into common stock with no addition
View filing at SEC.gov →Jaguar Health licensed U.S. commercial rights for Mytesi and Canalevia-CA1 to Future Pak for $16 million upfront plus $2 million contingent payment, driving Q1 2026 net revenue to approximately $19.3 million. The company is refocusing on crofelemer development for rare-disease in
View filing at SEC.gov →Jaguar Health's board authorized a new series of preferred stock with 2,000 shares available for issuance in exchange for cash or other securities. The filing establishes the rights, preferences, and terms for Series Q Perpetual Preferred Stock but does not disclose pricing or im
View filing at SEC.gov →